# CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

> **NCT04224571** · PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 208 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse

## Interventions

- **DRUG:** Bortezomib Injection
- **DRUG:** rituximab injection

## Key facts

- **NCT ID:** NCT04224571
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224571, "CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04224571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*